Integrated Report

Overview

The report describes record FY2025 revenue and profit, with growth in the Pharmaceutical and Nutraceutical Businesses. It highlights the U.S. launch of VOYXACT, the first therapy targeting APRIL, and reports that Scope 1 and 2 emissions were down 34.7% from FY2017. The group also expanded renewable-energy initiatives and continued work on its next-generation growth pipeline.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services